SEIA
ALXN

Signature Estate & Investment Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Signature Estate & Investment Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-198,908
Closed -$26.1M – 167
2019
Q2 		$26.1M Buy
198,908
+32,786
+20% +$4.23M 1.72% 16
2019
Q1 		$22.5M Buy
+166,122
New +$20.7M 1.51% 27

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Signature Estate & Investment Advisors's ALXN Position: Q3 2019 in Review

Signature Estate & Investment Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 198,908 shares — an estimated $26.1M sold.

Signature Estate & Investment Advisors first reported a position in ALXN in Q1 2019 and held it in 2 quarters. The position peaked at $26.1M in Q2 2019. 647 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Signature Estate & Investment Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Signature Estate & Investment Advisors sold 198,908 Alexion Pharmaceuticals shares in Q3 2019, an estimated $26.1M.
  • Signature Estate & Investment Advisors first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Signature Estate & Investment Advisors's Alexion Pharmaceuticals position peaked at $26.1M in Q2 2019.
  • 647 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Signature Estate & Investment Advisors's 13F filing for Q3 2019, filed 31 Oct 2019.